Most anticancer drugs are not able to cross the blood-brain barrier (BBB) effectively while surgery and radiation therapy cannot eradicate brain glioma cells and glioma stem cells (GSCs), hence resulting in poor prognosis with high recurrence rates. In the present study, a kind of multifunctional targeting daunorubicin plus quinacrine liposomes was developed for treating brain glioma and GSCs. ...

Elderly acute lymphoblastic leukemia (ALL) is a rare condition associated with low complete remission (CR) rate and short survival. In order to improve these results, we evaluate the efficacy and toxicity of Daunoxome, a liposomal daunorubicin, exhibiting toxicity profile and pharmacokinetic indices better than standard daunorubicin. In total, 15 consecutive patients with nonmature ALL were enr...

We evaluated the efficacy of daunorubicin  (40 mg/m(2)/day for 5 days, 200 mg/m(2)/cycle) combined with standard dose of cytarabine (100 mg/m(2)/day for 7 days) for acute myelogenous leukemia patients aged 65-74 years as induction therapy. Complete remission (81.3%) was achieved in 13 of 16 patients following the therapeutic program. The median duration of recovering absolute neutolophilic coun...

The effect of macelignan, a phytoestrogen, on P-gp function was investigated using multidrug resistant cancer cells overexpressing P-gp (NCI/ADR-RES) and the fluorescent P-gp substrates, daunorubicin and rhodamine 123. Macelignan (40 microM) increased the cellular accumulation of daunorubicin by approximately threefold in NCI/ADR-RES cells, whereas it did not alter the cellular accumulation of ...

This study was designed to examine the interaction of daunorubicin with human serum albumin (HSA) for the first time by fluorescence spectroscopy in combination with UV absorption and molecular modeling under simulative physiological conditions. The quenching mechanism was suggested to be static quenching according to the fluorescence measurement and the linearity of Scatchard plot indicated th...

Daunorubicin induces complete remissions during the first 5 days (25#{176}/o) or due to in about 500/0 of patients with acute prosepsis during the second and third week myelocytic leukemia. The median duration (25#{176}/o). Long-term survivals are more freof these remission is 26 mo. Failures are quent than in the other acute granulocytic mainly due to hemorrhages as a result of leukemias. diss...

Twenty-two patients with acute myeloid leukemiawere studied for in vitro drug sensitivity of the leukemic clonogenic cells in agar. The cells were preincubated for 1 hr with 1-/3-o-arabinofuranosylcytosine (ara-C; 0.15, 0.3, 0.6, 1.2, and 2.4 ¿tg/ml) or daunorubicin (0.018, 0.037, 0.075, 0.15, and 0.30 jig/ml), washed, and plated in agar, and cluster/colonies were counted after 10 days of incu...

We conducted a phase 3 randomized trial comparing 2 different doses of daunorubicin as induction chemotherapy in young adults (60 years of age or younger) with acute myeloid leukemia (AML). Of 383 patients who were analyzed, 189 received standard-dose daunorubicin (SD-DN, 45 mg/m² per day times 3 days) and 194 received high-dose daunorubicin (HD-DN, 90 mg/m² per day times 3 days) in addition to...

Acute myeloid leukemia (AML) in dogs is a rare disease with poor prognosis. In most subjects, palliative treatment or euthanasia is performed. A 3.5-year-old male castrated labrador with AML-M7, which was treated with induction polychemotherapy (8 cycles) using vincristine (0.5 mg/m(2)/cycle), daunorubicin (20 mg/m(2)/cycle), cytosine arabinoside (ARA-C, 100 mg/m(2)/cycle) and prednisolone (1 m...